A Faegre Drinker team led by corporate partners Matt Stamski and Brandon Mason advised medical device company Boston Scientific in its acquisition of Preventice Solutions, Inc., a privately held company, which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors — including short and long-term Holter monitors — to cardiac event monitors and mobile cardiac telemetry. The acquisition consists of an upfront cash payment of $925 million, and up to an additional $300 million in a potential commercial milestone payment.
The team also included corporate associates Hannah Costigan Cowles, Justin Hay, Jessica Parsons and Vanessa Tabler.
Additional advisors from the firm included labor and employment partner Dan Prokott and counsel Rhiannon Beckendorf; health care partner Steve Lokensgard and associate Alex Eschenroeder; FDA-regulated products partner Amy Judge-Prein and counsel Ted Lis; privacy, cybersecurity and data strategy partners Doriann Cain and Paul Luehr; intellectual property partners Jason Kraus and Rob Leonard; benefits and executive compensation partner Gayle Skolnik and associate Mark Rosenfeld; tax partner Charles Bybee; litigation partner Elsa Bullard; mergers and acquisitions insurance partner Kate Sherburne; and real estate partner Treasa Burke and associate Zachary Mahone.
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, the company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
Read Boston Scientific’s press release for more information on the deal.